(Total Views: 717)
Posted On: 10/31/2025 7:23:05 PM
Post# of 158792
San Antonio Breast Cancer Symposium
Poster Session 5
Day 4: December 12, 2025 12:30 PM--2:00 PM CST
PS5-02-30
Prolonged survival following PD-L1/PD-1 Immune checkpoint Inhibitor therapy after LERONLIMAB induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer.
She spoke eloquently 10 months ago...about smart bombs...trojan horses...permeable membrane leaks...absolutely passionate about Breast Cancer...lost a family member...who raised her.
"the goal on stage 4 cancers, unfortunately, it's very rare to have a complete remission and we're probably not going to cure this.
"Really nice data coming from Hope Rugo."
Dr. Milana V Dolezal, Stanford University School of Medicine, Stanford, Ca.
Poster Session 5
Day 4: December 12, 2025 12:30 PM--2:00 PM CST
PS5-02-30
Prolonged survival following PD-L1/PD-1 Immune checkpoint Inhibitor therapy after LERONLIMAB induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer.
She spoke eloquently 10 months ago...about smart bombs...trojan horses...permeable membrane leaks...absolutely passionate about Breast Cancer...lost a family member...who raised her.
"the goal on stage 4 cancers, unfortunately, it's very rare to have a complete remission and we're probably not going to cure this.
"Really nice data coming from Hope Rugo."
Dr. Milana V Dolezal, Stanford University School of Medicine, Stanford, Ca.
(14)
(0)
